



Press Release

Daiichi Sankyo Announces a Change to Corporate Officer

Tokyo, Japan - (Dec 16, 2024) – Daiichi Sankyo (TSE: 4568) today announced that its Board of Directors has approved a change to its Corporate Officer as follows.

Due to the sudden passing of Toshinori Agatsuma, Executive Officer, Head of R&D Division and Vice President of Research Function, R&D Division, we have appointed Yuki Abe, Corporate Officer, Vice President of Research Innovation Planning Department, Research Function, R&D Division as Head of R&D Division and Vice President of Research Function, R&D Division effective January 1, 2025.

Change to Corporate Officer (as of Jan 1, 2025)

Name	Current Position	New Position
Yuki Abe	Corporate Officer Vice President of Research Innovation Planning Department, Research Function, R&D Division.	Corporate Officer Head of R&D Division Vice President of Research Function

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:

Daiichi Sankyo Co., Ltd.

DS-PR@daiichisankyo.co.jp

Investor Relations Contact:

DaiichiSankyoIR_jp@daiichisankyo.com